Cargando…
Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation
Understanding the clinical significance of variants associated with hereditary cancer risk requires access to a pooled data resource or network of resources—a “cancer gene variant commons”—incorporating representative, well-characterized genetic data, metadata, and, for some purposes, pathways to ca...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305920/ https://www.ncbi.nlm.nih.gov/pubmed/34357113 http://dx.doi.org/10.3390/jpm11070646 |
_version_ | 1783727686669041664 |
---|---|
author | Majumder, Mary A. Blank, Matthew L. Geary, Janis Bollinger, Juli M. Guerrini, Christi J. Robinson, Jill Oliver Canfield, Isabel Cook-Deegan, Robert McGuire, Amy L. |
author_facet | Majumder, Mary A. Blank, Matthew L. Geary, Janis Bollinger, Juli M. Guerrini, Christi J. Robinson, Jill Oliver Canfield, Isabel Cook-Deegan, Robert McGuire, Amy L. |
author_sort | Majumder, Mary A. |
collection | PubMed |
description | Understanding the clinical significance of variants associated with hereditary cancer risk requires access to a pooled data resource or network of resources—a “cancer gene variant commons”—incorporating representative, well-characterized genetic data, metadata, and, for some purposes, pathways to case-level data. Several initiatives have invested significant resources into collecting and sharing cancer gene variant data, but further progress hinges on identifying and addressing unresolved policy issues. This commentary provides insights from a modified policy Delphi process involving experts from a range of stakeholder groups involved in the data-sharing ecosystem. In particular, we describe policy issues and options generated by Delphi participants in five domains critical to the development of an effective cancer gene variant commons: incentives, financial sustainability, privacy and security, equity, and data quality. Our intention is to stimulate wider discussion and lay a foundation for further work evaluating policy options more in-depth and mapping them to those who have the power to bring about change. Addressing issues in these five domains will contribute to a cancer gene variant commons that supports better care for at-risk and affected patients, empowers patient communities, and advances research on hereditary cancers. |
format | Online Article Text |
id | pubmed-8305920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83059202021-07-25 Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation Majumder, Mary A. Blank, Matthew L. Geary, Janis Bollinger, Juli M. Guerrini, Christi J. Robinson, Jill Oliver Canfield, Isabel Cook-Deegan, Robert McGuire, Amy L. J Pers Med Article Understanding the clinical significance of variants associated with hereditary cancer risk requires access to a pooled data resource or network of resources—a “cancer gene variant commons”—incorporating representative, well-characterized genetic data, metadata, and, for some purposes, pathways to case-level data. Several initiatives have invested significant resources into collecting and sharing cancer gene variant data, but further progress hinges on identifying and addressing unresolved policy issues. This commentary provides insights from a modified policy Delphi process involving experts from a range of stakeholder groups involved in the data-sharing ecosystem. In particular, we describe policy issues and options generated by Delphi participants in five domains critical to the development of an effective cancer gene variant commons: incentives, financial sustainability, privacy and security, equity, and data quality. Our intention is to stimulate wider discussion and lay a foundation for further work evaluating policy options more in-depth and mapping them to those who have the power to bring about change. Addressing issues in these five domains will contribute to a cancer gene variant commons that supports better care for at-risk and affected patients, empowers patient communities, and advances research on hereditary cancers. MDPI 2021-07-08 /pmc/articles/PMC8305920/ /pubmed/34357113 http://dx.doi.org/10.3390/jpm11070646 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Majumder, Mary A. Blank, Matthew L. Geary, Janis Bollinger, Juli M. Guerrini, Christi J. Robinson, Jill Oliver Canfield, Isabel Cook-Deegan, Robert McGuire, Amy L. Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation |
title | Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation |
title_full | Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation |
title_fullStr | Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation |
title_full_unstemmed | Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation |
title_short | Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation |
title_sort | challenges to building a gene variant commons to assess hereditary cancer risk: results of a modified policy delphi panel deliberation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305920/ https://www.ncbi.nlm.nih.gov/pubmed/34357113 http://dx.doi.org/10.3390/jpm11070646 |
work_keys_str_mv | AT majumdermarya challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT blankmatthewl challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT gearyjanis challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT bollingerjulim challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT guerrinichristij challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT robinsonjilloliver challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT canfieldisabel challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT cookdeeganrobert challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation AT mcguireamyl challengestobuildingagenevariantcommonstoassesshereditarycancerriskresultsofamodifiedpolicydelphipaneldeliberation |